分析伊沙佐米联合来那度胺及地塞米松治疗复发难治性多发性骨髓瘤的疗效与安全性  

Clinical Effectiveness and Safety of Ixazomib Combined With Lenalidomide and Dexamethasone in the Treatment of Recurrent Refractory Multiple Myeloma

作　　者：毛沛沛[1] MAO Peipei(Department of Hematology,Nanyang Central Hospital,Nanyang Henan 473000,China)

机构地区：[1]南阳市中心医院血液内科,河南南阳473000

出　　处：《临床研究》2023年第2期96-99,共4页Clinical Research

摘　　要：目的 分析伊沙佐米加来那度胺和地塞米松对复发难治性多发性骨髓瘤(MM)的疗效和安全性。方法 2021年1月至2022年6月南阳市中心医院收治复发难治性MM患者总共68例,结合随机数字表法将其中34例分为对照组(予以来那度胺和地塞米松),余下34例分为观察组(在前组基础上加以伊沙佐米),比较两组的疗效,化疗前后生化指标(骨髓浆细胞占比、血沉、M蛋白含量和β2-微球蛋白),化疗前后免疫指标(免疫球蛋白IgA、IgG以及IgM水平),副反应出现情况。结果 观察组治疗有效率(94.12%)高出对照组(70.59%),差异有统计学意义(P<0.05)。治疗前,两组的骨髓浆细胞占比、血沉、M蛋白、β2-微球蛋白、IgA、IgG、IgM水平相比差异无统计学意义(P>0.05);治疗后,两组的骨髓浆细胞占比、血沉、M蛋白、β2-微球蛋白、IgA、IgG、IgM水平均较前降低,差异有统计学意义(P<0.05),且观察组的骨髓浆细胞占比、血沉、M蛋白、β2-微球蛋白、IgA、IgG、IgM水平均低于对照组,差异有统计学意义(P<0.05)。两组用药期间血小板或中性粒细胞减少、贫血、感染、皮疹、胃肠道反应、乏力及头晕嗜睡副反应出现相比,差异无统计学意义(P>0.05)。结论 伊沙佐米加来那度胺和地塞米松对复发难治性MM患者疗效理想,能控制其病情进展,改善其免疫功能,且不会显著增加副反应出现,安全性高。Objective To analyze the clinical effectiveness and safety of Ixazomib, lenalidomide and dexamethasone in treatment of the recurrent refractory multiple myeloma(MM). Methods A total of 68 recurrent refractory MM patients treated in our hospital from January 2021 to June 2022 were selected. According to random number table, 34 cases taking lenalidomide and dexamethasone were included in the control group;34 cases taking Ixazomib, lenalidomide and dexamethasone were included in the observation group. The efficacy, biochemical indicators(proportion of bone marrow plasma cells, erythrocyte sedimentation rate, M protein and β2-microglobulin content), immune indicators(immunoglobulin IgA, IgG and IgM levels) before and after chemotherapy, and the occurrence of side reactions were compared between two groups. Results The effective treatment rate in the observation group(94.12%) was higher than control group(70.59%), with significant difference(P<0.05);Before therapy,there were no significant between-group differences about the bone marrow plasmacyte ratios, erythrocyte sedimentation rate, M protein and β2-microglobulin, IgA, IgG and IgM levels(P >0.05);After therapy, the bone marrow plasmacyte ratios, erythrocyte sedimentation rate, M protein and β2-microglobulin, IgA, IgG and IgM levels in two groups were significantly lower than before(P<0.05);The bone marrow plasmacyte ratios, erythrocyte sedimentation rate, M protein and β2-microglobulin, IgA, IgG and IgM levels in the observation group were even lower than control group, with significant differences(P<0.05);During medication, there were no significant between-group differences about the incidences of toxic reactions like thrombocytopenia,neutropenia, anemia, infection, skin rash, gastrointestinal reaction, weakness, dizziness and drowsiness(P>0.05). Conclusion Ixazomib, lenalidomide and dexamethasone have ideal efficacy in patients with recurrent refractory MM, can control their disease progression and improve their immune function without significantly increas

关 键 词：伊沙佐米 来那度胺 地塞米松 多发性骨髓瘤 疗效 安全性 

分 类 号：R551.3[医药卫生—血液循环系统疾病]